{"name":"Adocia","slug":"adocia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ADO09 formulation","genericName":"ADO09 formulation","slug":"ado09-formulation","indication":"Other","status":"phase_1"},{"name":"BC Pram Ins","genericName":"BC Pram Ins","slug":"bc-pram-ins","indication":"Other","status":"phase_1"},{"name":"BC106 insulin lispro","genericName":"BC106 insulin lispro","slug":"bc106-insulin-lispro","indication":"Other","status":"phase_1"},{"name":"BioChaperone human insulin","genericName":"BioChaperone human insulin","slug":"biochaperone-human-insulin","indication":"Other","status":"phase_1"},{"name":"Humulin®","genericName":"Humulin®","slug":"humulin","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"BioChaperone PDGF-BB","genericName":"BioChaperone PDGF-BB","slug":"biochaperone-pdgf-bb","indication":"Chronic diabetic foot ulcers","status":"phase_3"},{"name":"GlucaGen® HypoKit®","genericName":"GlucaGen® HypoKit®","slug":"glucagen-hypokit","indication":"Severe hypoglycemia in patients with diabetes","status":"phase_3"},{"name":"Humalog® Mix25","genericName":"Humalog® Mix25","slug":"humalog-mix25","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Symlin®","genericName":"Symlin®","slug":"symlin","indication":"Type 1 diabetes mellitus (adjunct to insulin therapy)","status":"marketed"}]}],"pipeline":[{"name":"ADO09 formulation","genericName":"ADO09 formulation","slug":"ado09-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BC Pram Ins","genericName":"BC Pram Ins","slug":"bc-pram-ins","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BC106 insulin lispro","genericName":"BC106 insulin lispro","slug":"bc106-insulin-lispro","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BioChaperone PDGF-BB","genericName":"BioChaperone PDGF-BB","slug":"biochaperone-pdgf-bb","phase":"phase_3","mechanism":"BioChaperone PDGF-BB is a formulation of platelet-derived growth factor BB designed to enhance wound healing and tissue repair by promoting angiogenesis and cell proliferation.","indications":["Chronic diabetic foot ulcers","Chronic wounds"],"catalyst":""},{"name":"BioChaperone human insulin","genericName":"BioChaperone human insulin","slug":"biochaperone-human-insulin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GlucaGen® HypoKit®","genericName":"GlucaGen® HypoKit®","slug":"glucagen-hypokit","phase":"phase_3","mechanism":"GlucaGen HypoKit is a glucagon formulation designed to rapidly raise blood glucose levels in patients experiencing severe hypoglycemia.","indications":["Severe hypoglycemia in patients with diabetes"],"catalyst":""},{"name":"Humalog® Mix25","genericName":"Humalog® Mix25","slug":"humalog-mix25","phase":"phase_3","mechanism":"Humalog® Mix25 is a premixed insulin formulation combining rapid-acting insulin lispro with intermediate-acting insulin isophane to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Humulin®","genericName":"Humulin®","slug":"humulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Symlin®","genericName":"Symlin®","slug":"symlin","phase":"marketed","mechanism":"Symlin (pramlintide) is an amylin analog that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial blood glucose excursions in diabetes.","indications":["Type 1 diabetes mellitus (adjunct to insulin therapy)","Type 2 diabetes mellitus (adjunct to insulin therapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPMHQ5dnVXcUZlVEN5VTE3RWZLZjNCRmNtMVVSSlNLcGsyS1IxUmp6TVpfeEhhVkdVUG9XNmx4OTVQVktmVlZpMkotdmx6QnI5QWJTV2IyUHpWd3ZKb1pSUVJBQXdwRmxPMG00bTQ0TE1OeGRiSFJQMWxwMGFkNHRnMm8xMmtYWTAtSmp4djlqeGNoYnBYRjJVMnBWb19xdUNhYkNPcg?oc=5","date":"2025-11-12","type":"pipeline","source":"PharmaTimes","summary":"Adocia unveils new long-acting peptide platform for diabetes and obesity - PharmaTimes","headline":"Adocia unveils new long-acting peptide platform for diabetes and obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMEtXUUhOM2V6MXU0bFJCd0pYWW5RbnFnQTJnRUJKZ0czbmpyaVFOVGJORTFCSi1CTGlqek5JZzc1RHpxbDdDWkItTlYyU3JSejdhODBNOW93M2ROcnRtVHlhWTdnZTFqQ1ZoREFvSVRpMERFbnFzZ0hvbXI4UlU4TExuVUdYOVBVZEw3TUM2NlgxVmQzN0d5M3NYMURrWkNYV1Q3NmkxRVg?oc=5","date":"2025-10-28","type":"trial","source":"BioWorld News","summary":"Adocia’s Biochaperone Lispro phase III T1D data positive in China - BioWorld News","headline":"Adocia’s Biochaperone Lispro phase III T1D data positive in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUXEzSHlrYnd0Q2RERUVGWUVGNUp1Qk44bUlFWFcwNFNHXzRoNDlpcVBubmZ0UkE3X3F4dEhLTEZDNzBoeG5sazEwbmlQQkRfaWdRU0h1YzFTYlZYTTJvLTJZX1RhQllKNWJsV194TzNLM1JZeVdocWJ3T3llOU5sNGhXQUptMEJZRTVuSEJZT0swYkJESXVxbkZsZ05JOU9MclE?oc=5","date":"2025-10-15","type":"trial","source":"PharmaTimes","summary":"Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes - PharmaTimes","headline":"Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNUWpuT1NNNHhSMXluSXpXSVBaZi1FLVl0NDVIaE5BRUE1SEhiNVdSZzd4cnRTYnhoSjd0ZkZMSkY3WmwtUXpDVHNwLWd3Ri1EMWRkSWkxdHFtMDFJSndqc2VlUElTbEIyWl9ub3pwNWxNd1dXanBSa2JQQnJRcmdTZHpSTVpuZkoxTTFGR2FqUHdsNVVLaXYyZTh5Q3VGVDhQYk5wQlpBQjR5cnZONnQzcS0xS2hUYkpZdkQweVFMX1IxS3JWVXNRVlR5dzFiM0tJNWxpem8tWEJLd1RZZEt5N2Q0T0RKMHBqRlJzS0UtamhWS1RzdlI0RlUtZXVsWThhbl9obmdfcmUwa1dXaHZiVmpKUUZiUWU2NHY1eGpXN1NRZ1BiUU0taW5rWGlHcWZEeVRoMlJzN0NPVVduRmNZRE9MQm10TXc?oc=5","date":"2025-07-25","type":"trial","source":"businesswire.com","summary":"ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D - businesswire.com","headline":"ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChapero","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNU3VNaHhUTkZxalJ5ZGZsd2pLRmU2cVRJdjhxMDAzbzRhRGJkNXkzcGs4MkhtRWRzNld3MGt4T3lscm1SYTZfVVhkbnlyNEhMbWJKM2tBYXRDTGFlb0pfXzRZTHJjQXBUVVF6S2J4VEx6b3VzR0pvTEI2Y2VrbDF5Q080MVI4TUVyVWZLbHdsX0p6M2xLV2ppdkFUd1EwWXdsZWxheXlmNGZfZ1dwUFR3Mg?oc=5","date":"2025-07-03","type":"trial","source":"Healio","summary":"Novel GLP-1/GLP-2 agent safe, confers weight loss in early study - Healio","headline":"Novel GLP-1/GLP-2 agent safe, confers weight loss in early study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOYzJrQ1ZTWTR0MXE5Z0RuM2VLMGlZRVptM1pZNHJPNFV4bWNNRlBrZWEzdDBZTk1wdHZ1QnpzejdXVVQwc0M5aTNUMy1fN01xRFhNcTlTZVduaGxIZnh3TGRkNVpJMXA2QkVHekpOcEoyQlRpUUhRUWgzQlU4MVNzNg?oc=5","date":"2022-06-22","type":"pipeline","source":"labiotech.eu","summary":"Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin - labiotech.eu","headline":"Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE12RWw5dHM4M2NhS1luT3BHQWpvcXJiRXJIVllORkFhQ2xiYWx6b1RyMWZ0bkVUc2hhT1pzYUVMYVp6TER3S25TaFFuVXIwVWh2MVNIWmdkckREa0taUkc4VjBHeVZTdlhCbGM3aXd3?oc=5","date":"2019-07-10","type":"pipeline","source":"labiotech.eu","summary":"The Top 10 Biotechs You’ll Find in Lyon - labiotech.eu","headline":"The Top 10 Biotechs You’ll Find in Lyon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQR04zMzlsTngzc19qeXRldU81SlJqb1R0ekpzOUhYb2JQS1BuZC1lVW9wT3BDY2NVUU15WF80TWxiMW8wdHBTZzh2cGFlS0RoRFVMb2xCdlJtV25oYU1vQm1IcE1wNUcteTR0cVNLQnowWVV4X1FpOGdUQVphR3hSN3pkUjlTTEpldWxydEpJblFXVUx3UFBaeTRZVTJKOEFEUDJEeGx3?oc=5","date":"2018-10-11","type":"patent","source":"Life Sciences Intellectual Property Review","summary":"Eli Lilly takes Adocia to court over insulin patents - Life Sciences Intellectual Property Review","headline":"Eli Lilly takes Adocia to court over insulin patents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9qejVGS2h3VVJLS2pOb1NGTWxKMF9QSm9oTjB4ZWhoTHVfNnB2TmlPNVYzLVJmZk1qaTVlOEYwLTgzWmJqLUc5ZkpWNUFwX2FBVzlGb3FR?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Adocia SA (ADOC.PA) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Adocia SA (ADOC.PA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOWDdYWEhZVW83NTN5dTc5TWVHaWw4bzFNazRQN2Q4cVB4TEN5NjNfN1RWMkVFbGxMX2NJMXJNNFVsZVA3NW5OdFhmYXN1S3NDdTZ0a0tsRGlhVjVqQlV3V3EzdEtrMVAyVkpIX1RXZmpiNC1rRHRjMXBOdTEzV1RMcElkZS10ZS15M2pBc3lDUU5ES29TX1dyOFpOR1J5UFpONTRwc0VxMzN3MEhJYWVER2d2cHFnUjRjeUlwNGVRUDV0a0pn?oc=5","date":"2014-12-19","type":"pipeline","source":"Fierce Pharma","summary":"Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology - Fierce Pharma","headline":"Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":4,"phase_3":3,"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}